MARKETS / NASDAQ / HYPD
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Hyperion Defi, Inc. HYPD

10 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$813,455
▲ 1318.8% vs FY2024
EPS · FY25
$-9.40
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-324.1%
Net margin · FY25
-5570.6%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 813,455.00
Revenue, FY2025 · full 10-year series below
Revenue Net income
0.0040.0080.0120.0160.0-0.02016201920222025
0.0040.0080.0120.0160.0-0.02016201920222025

The company lost 5571 cents on every revenue dollar this year.

Per share
USD -9.40
Diluted EPS, FY2025
EPS
0.40.81.2-9.402016201920222025
0.40.81.2-9.402016201920222025

The company pays no cash dividend.

Profitability
-324.1%
Return on equity, FY2025
ROE
0.250.50.751-324.1%2016201920222025
0.250.50.751-324.1%2016201920222025
Operating margin-5743.5%
Net margin-5570.6%
Return on assets-163.5%

Each USD of equity lost 324 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
−16.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−16.5%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.01B
Shares outstanding, FY2025
0.000.012016201920222025
0.000.012016201920222025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 51.8M
total assets, end of FY2025
Total assetsUSD 51.8M
EquityUSD 41.1M
CashUSD 6.4M
Current ratio2.68×

Equity funds 79% of total assets.

History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
0.0
0.0
0.0
·
0.0
0.0
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
−0.0
·
·
·
·
·
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−9.40
−59.81
−53.15
−0.83
−0.49
−0.94
−1.47
−1.82
−2.19
−1.56
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
−324.1
·
−207.8
−148.6
−71.4
−146.2
−147.9
−157.1
−126.7
−117.4
Shares out B
0.01
0.00
0.00
0.04
0.03
0.02
0.02
0.01
0.00
0.00

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
35 of 35
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed